Thus, we have taken several approaches to rigorously test the specific role of Src in thyroid cancer, including genetic approaches (shRNA and expression of a drug-resistant c-Src gatekeeper mutation) and treatment with dasatinib doses < 100 nM to control for off-target effects, along with treatment with two distinct Src inhibitors, which show similar anti-tumor responses [10,11,12,24]. This evidence concerns the gene SRC and neoplasm.